A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 310 participants.
Also called NCT01652703
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 310 participants
- Sponsor
- Registry
-
NCT01652703
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01652703. Randomized; triple masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2013-05-14 (actual). Results posted on 2015-10-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
- Acronym
- AMG145
- Condition
- Hypercholesterolemia and High Risk for Cardiovascular Events
- Intervention (Biological)
- Evolocumab
- Intervention (Other)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01652703- Content hash
9f663e5e8336cbe2adbac647aef9aff3b922e97cee224d77c6e2c82384978c5b